Psoriasis Drugs Market Analysis - Global Industry Size, Share, Trends and Forecast, 2018 – 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC851

Introduction

Psoriasis is a long-lasting disease which forms patches at skin surface. It involves rapid development of cells which produce silver scales, thick, and make the skin, flaky, red, dry and itchy. Various types of psoriasis are guttate, vulgaris, pustular, inverse, erythrodermic, palmoplantar, nail, and scalp psoriasis. In addition, approximately 10%-12% among the populations has severe diagnosis and suffers from different forms of psoriasis and 85%-90% of the people fall under major to minor category of psoriasis. At present, long-lasting cure is not available for this syndrome. However in order to halt the growth of cells on the surface of the skin, preventative measures can be adopted. Psoriasis can be treated either with biopharmaceuticals or pharmaceuticals therapies through systemic and topical process. These medications when directed, either consumed orally, or by applying on the skin,  or through inoculations, specifically block parts of immune system process by targeting phosphodiesterase type 4, tumour necrosis factor, and interleukin among others.

Market Dynamics

Availability of better and advanced diagnostic devices results in constructing assurance in people, thereby resulting in adoption of treatment. Rising healthcare expenditure is also stimulating market growth. Due to the high cost in drug development, increasing availability of various generic products, side effects from the biologics and systemic medication such as liver and kidney damage, high blood pressure, infection, and cancer of the lymph nodes, also health insurance issues, low efficacy of the product and lack of access to healthcare may impede market growth. Increasing demand of psoriasis medicines in emerging economies, development of long-lasting drugs is expected to boost psoriasis market in forthcoming years.

Market Classification and Overview

The market can be bifurcated on the basis of therapeutic class, drugs, and geography. By therapeutic class, psoriasis drugs market can be segmented into tumor necrosis factor inhibitor, interleukin inhibitors, and vitamin-D analogues. Further tumor necrosis factor inhibitor is sub-classified into adalimumab, etanercept, infliximab. Also, interleukin inhibitors are sub-segmented into ustekinumab, secukinumab, ixekizumab, brodalumab. Vitamin-D analogues are further basified into calcitriol, calcipotriol, tacalcitol, and among others. By drugs, psoriasis drugs market can be segmented into topicals, systemic, and biologics. Topicals further segmented into over-the-counter (OTC) topicals, topical non-steroids, topical steroids.Systemic further sub-segmented into retinoid, cyclosporine, and methotrexate. Biologics sub- classified into tumor necrosis factor (TNF) inhibitors, interleukin 12 and 23 (IL-12/23) inhibitors, interleukin 17 (IL-17) inhibitors, and T-cell inhibitors. On the basis of geography, the psoriasis drugs market can be segmented into North America, Latin America, Europe, Middle East & Africa (MEA) and Asia-Pacific.

 

Report Coverage

Market

Psoriasis Drugs Market

Analysis Period

2015 – 2026

Historic Data

2015 – 2016

Base Year

2017

Forecast Data

2018 – 2026

Market Stratification

Therapeutic Class, Drugs, Geography

Regional Scope

North America, Europe, Asia-Pacific, Latin America, Middle East and Africa (MEA)

Report Coverage

Market Trends, Drivers, Restraints, Porter's Five Forces Analysis,

Competitive Analysis, Player Profiling, Value Chain Analysis

 

Market Participants

Some of the major players involved in the supply of psoriasis drugs market include Johnson & Johnson, Novartis International AG, Pfizer Inc, Merck and Co. Inc, Celgene Corporation, Janssen Biotech Inc, Stiefel Laboratories Inc, Takeda Pharmaceutical Company Limited, Amgen Inc., and AbbVie among others.

Market Segmentation

Market By Therapeutic Class

  • Tumor Necrosis Factor Inhibitor

Adalimumab

Etanercept

Infliximab

  • Interleukin Inhibitors

Ustekinumab

Secukinumab

Ixekizumab

Brodalumab

  • Vitamin-D Analogues

Calcitriol

Calcipotriol

Tacalcitol

Others

Market By Drugs

  • Topicals

Over-the-counter (OTC) topicals

Topical non-steroids

Topical steroids

  • Systemic

Retinoid

Cyclosporine

Methotrexate

  • Biologics

Tumor Necrosis Factor (TNF) Inhibitors

Interleukin 12 and 23 (IL-12/23) Inhibitors

Interleukin 17 (IL-17) Inhibitors

T-cell Inhibitors

Market By Geography

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • UK
  • France
  • Germany
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Chile
  • Rest of LATAM

Middle East and Africa (MEA)

  • South Africa
  • Saudi Arabia
  • Rest of MEA

 


Cart Summary


1